MABXIENCE RESEARCH SL.
Location
Madrid
Founded
2015-12-23
Website
Risk Signals
16 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about MABXIENCE RESEARCH SL.
Live alerts from global media, monitored by Business Radar
2025-05-26 (pharmasource.global)
mAbxience Signs Licensing Deal with Abiogen Pharma -
mAbxience, a Fresenius Kabi majority-owned CDMO with additional ownership from Insud Pharma, has entered a strategic licensing agreement with Italy-based Abiogen Pharma to develop and…
Read more
2025-05-26 (informatori.it)
Abogen and Mabxience together to bring a new biosimilar to Italy <
Abiogen Pharma and Mabxience have announced the signature of a strategic agreement for the marketing in Italy of a biosimilar candidate. According to the terms, abogen will manage marketing and distribution on… Continued
Read more
2024-10-03 (contractpharma.com)
Teva, mAbxience Expand Collaboration to Include an Additional Oncology Biosimilar |
Aim to provide cost-effective, high-quality biosimilar treatments that address critical unmet needs in oncology care.
Read more
2024-04-04 (fiercepharma.com)
Teva, forging ahead with new strategy, inks biosimilar deal with Spain's mAbxience
As Teva advances its Pivot to Growth strategy under CEO Richard Francis, the company is making good on its pledge to beef up its biosimilar pipeline through outside deals. | Teva has unveiled a fresh in-licensing accord with Spain’ s mAbxience to chip in on an investigational biosimilar spanning
Read more
2023-09-21 (contractpharma.com)
Abbott Labs, mAbxience Enter Biosimilars Mfg. Pact |
mAbxience will manufacture the biosimilars at its GMP approved facilities in Spain and Argentina.
Read more
2023-09-20 (nasdaq.com)
Abbott Inks Deal With MAbxience To Commercialize Biosimilar Molecules In Emerging Markets
(RTTNews) - Abbott Laboratories (ABT) announced Wednesday an agreement with Spain-based global biotech firm mAbxience Holdings S.L. to commercialize several biosimilars focusing on oncology, women's health and respiratory diseases in emerging markets.
Read more
2022-04-18 (prnewswire.com)
FDA Approves Alymsys® (bevacizumab-maly), a Biosimilar of Bevacizumab by Amneal Pharmaceuticals, Inc., developed by mAbxience
/PRNewswire/ -- Brand Institute is proud to announce its successful partnership with Amneal Pharmaceuticals in developing the brand name ALYMSYS®, under which...
Read more
2022-04-05 (contractpharma.com)
Insud Pharma and Fresenius Kabi to Accelerate the Growth of mAbxience |
Agreement will bring new business to the Spanish biotech, which is expanding its manufacturing capabilities.
Read more
2021-04-09 (citeline.com)
Mabxience Allies With Zentiva For European Bevacizumab Launch
Mabxience and Zentiva have partnered to launch the Alymsys bevacizumab biosimilar rival to Avastin that recently received a pan-European marketing authorization.
Read more
(economictimes.com)
Intas in pact with Spanish drug maker mAbxience to sell biosimilar etanercept in over 150 countries -
mAbxience, a majority-owned company of German drug maker Fresenius Kabi, also has partial ownership from Insud Pharma, will be responsible for the development, manufacturing, and supply of the Etanercept biosimilar.
Read more
(pharmaceutical-technology.com)
Amneal partners with mAbxience for denosumab biosimilars - Pharmaceutical Technology
Amneal adds Prolia and Xgeva biosimilars to its oncology portfolio which already has three biosimilars products launched in the US.
Read more